The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / February / Breaking the Biomarker Bottlenecks Part 2
Oncology Bioinformatics Precision medicine Companion diagnostics Omics Technology and innovation Insights Opinion and Personal Narratives Molecular Pathology Voices in the Community

Breaking the Biomarker Bottlenecks: Part 2

Industry leaders from AstraZeneca, Leica Biosystems, and Danaher share their insights on AI’s power to democratize access to precision medicine

02/16/2026 Interview 6 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll

Share

Clinical Scorecard: Breaking the Biomarker Bottlenecks: Part 2

At a Glance

CategoryDetail
ConditionTumor treatment selection
Key MechanismsAI-powered diagnostics for improved accuracy and consistency in biomarker analysis
Target PopulationPatients with tumors requiring precise therapy selection
Care SettingOncology clinics and diagnostic laboratories

Key Highlights

  • AI ensures reproducibility in diagnostic results across different labs
  • AI provides accurate quantitative results critical for therapy decisions
  • AI captures complex cellular interactions beyond human interpretation
  • Multimodal biomarkers powered by AI enhance patient selection strategies
  • AI aids in monitoring therapy response for tailored treatment adjustments

Guideline-Based Recommendations

Diagnosis

  • Utilize AI-enabled assays for consistent biomarker interpretation
  • Incorporate proteomics and cellular structure analysis in diagnostics

Management

  • Employ AI for therapy selection based on comprehensive biomarker data
  • Adjust treatment regimens based on AI analysis of therapy response

Monitoring & Follow-up

  • Use AI to consistently evaluate cellular structures during follow-ups
  • Implement AI-driven insights to refine treatment decisions

Risks

  • Inconsistent interpretations by pathologists can lead to misdiagnosis
  • Lack of regulatory clarity may hinder the adoption of AI diagnostics

Patient & Prescribing Data

Patients with various tumor types requiring personalized treatment

AI can identify optimal therapy regimens based on detailed biomarker analysis

Clinical Best Practices

  • Foster partnerships with technology and data analytics companies
  • Advocate for regulatory clarity regarding AI diagnostics
  • Adapt business models to accommodate novel AI-driven technologies

Related Resources & Content

  • Breaking the Biomarker Bottlenecks: Part 2

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.